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Introduction
Osteoarthritis (OA) is a common clinical problem in animals [1,2], as well as the most common 
joint disease and one of the most frequent causes of physical impairment in humans [3]. As part 
of the OA-complex, elastoviscosity of the synovial fluid is abnormally low [4], and thus the use of 
viscosupplementation, for example intra-articular injections of high molecular-weight hyaluronic-
acid, has been implemented as part of the treatment for OA in humans [5,6], as well as animals (e.g. 
horses) [7].
2.5% Polyacrylamide hydrogel (PAAG) is a non-toxic and non-immunogenic biocompatible 
polymer gel consisting of 97.5% sterile water and 2.5% cross-linked polyacrylamide [8,9] (Arthramid® 
Vet, Contura International A/S, 2860, Søborg, Denmark), and its biocompatibility in soft tissues has 
been demonstrated [10-12]. Also, PAAG is a non-particulate homogenous gel similar to hyaluronic 
acid in overall structure and tissue compatibility [11], but with a longer-lasting viscous effect, as it is 
non-degradable [8]. PAAG has also proven to be safe in humans over more than 16 years of use for 
the augmentation of connective tissues [12,13], and in horses as well [14-16]. Experimental studies 
supported by histopathological observations have shown that PAAG exerts its effect via integration 
over time within the soft tissues, through a combination of vessel in-growth and molecular water 
exchange [8,11].
Recent clinical and experimental trials have investigated the effect of PAAG on improving 
clinical signs of OA in horses [14-16], and in a goat model [17]. Forty three horses, older than two 
years with OA located within only one joint were treated intraarticularly with PAAG and were 
followed-up at 1, 3, 6, 12 and 24 months. At 6 months, approximately 79% of horses were sound 
(non-lame) [15]. At 12 months, 81% of the horses from the same study population were sound [15]. 
At 24 months follow-up, 82.5% of horses were sound and no side effect was observed in the treated 
joints during the study period [15]. In this study, there was a significant decrease in lameness score 
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Abstract
A 2.5% Polyacrylamide Hydrogel (PAAG)a was tested for treatment of Osteoarthritis (OA) in a goat 
model (transection of medial collateral ligament, bisection of medial meniscus and partial-thickness cartilage 
incisions of medial tibial plateau) with highly encouraging results. The objective was to describe preliminary 
observations of the mechanisms of action of PAAG in OA joints, based on MRI, pathology and joint capsule 
elasticity investigations. A randomized controlled study was conducted on an OA knee model in goats: treatment 
group (intraarticular PAAG), control group (intraarticular saline). Magnetic Resonance Imaging (MRI) was 
performed prior to surgery, 3, 4, 5 and 7 months post-surgery. Seven months post-surgery, gross pathology and 
histopathology, including immunohistochemistry for nerve endings, were performed on both knees. Joint capsule 
elasticity of the knees was measured in both groups. 
MRI showed reduction followed by stabilization of OA lesions after PAAG treatment. At gross pathology, 
PAAG was seen adhering to synovial membrane. Histopathology showed that intraarticular PAAG injection 
added to the thickness of the synovial membrane by allowing angiogenesis, collagen and synovial cell increase; 
PAAG was integrated into the synovial membrane. Nerve endings were intact with normal morphology and 
numbers. Joint capsule elasticity investigation showed that treated knees had a higher elasticity when compared 
to control knees. This study presents preliminary observations of the mechanisms of action of PAAG on OA 
joints: (1) Pathology and joint capsule elasticity suggest that PAAG by acting on synovial membrane may reduce 
overall joint capsule stiffness, a major source of pain in OA. (2) MRI and pathology revealed stabilization of OA 
lesions in PAAG treated goats, possibly caused by the high viscosupplementation of PAAG.
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from baseline to 1, 3, 6, 12 and 24 months (p<0.0001) and a significant 
association with joint effusion (p<0.0001). Estimates for Odds Ratio 
(OR) showed that the effect of treatment increased over time (OR 
for lower lameness from month 1 to 24 relative to baseline increased 
from 20 to 58). A comparative prospective study has demonstrated 
that horses with OA treated with PAAG significantly improved 
their clinical signs when compared to horses with OA treated with 
Triamcinolone acetonide combined with hyaluronic acid [14]. 
Another report has shown that PAAG effectively relieved lameness in 
horses with distal interphalangeal joint OA [16]. A recent randomized 
controlled pilot study using an experimental OA model in goats has 
shown that PAAG was integrated into the synovial membranes of the 
injected joint, and significantly improved the lameness caused by OA, 
with 75% of the cases becoming sound at 4 months post treatment 
evaluation [17].
The purpose of this paper was to describe the preliminary 
observations of the mechanisms of action of a PAAG in OA joints. 
These observations were based on the results from MRI, joint 
pathology and joint capsule elasticity investigations.
Methods
This experimental study was conducted between June 2011 
and February 2013 and was approved by the Danish Council for 
Animal Experimentation. This randomized controlled study was 
conducted involving 6 goats with induced OA on the left knee joint. 
OA was surgically induced by the transection of the medial collateral 
ligament, the bisection of the medial meniscus at its midpoint and 
partial-thickness incisions of the cartilage of the medial tibial plateau 
[18]. Goats were allowed free exercise, and 3 months after surgery 
they were randomly divided into 2 groups: Treatment group (n=4) 
which received PAAG and control group (n=2) which received saline 
solution. PAAG and saline solution were injected intraarticularly 
(1 ml). All goats were videotaped on a treadmill for lameness 
examination.
Magnetic resonance imaging investigation
MRI of the left knee was performed prior to surgery, at the time 
of joint injection (3 months) and 4, 5 and 7 months post-surgery. 
T1 (coronal and sagittal) T2/PD (coronal and transverse) and Stir 
(sagittal and coronal) weighted MRI images using a 0.2 T scannerb 
(Knee coil) were obtained to assess OA.
Histopathological investigation
The goats were euthanized 7 months after surgery, then gross 
pathology and histopathology, including immunohistochemistry 
for nerve endings, was performed on both femorotibial joints and 
elbows. On the operated knee, special attention was given to the 
location of the gel, the surgical site (the medial meniscus and the 
articular cartilage of the medial tibia), the synovial membrane, and 
the articular cartilage. The macroscopic appearance of the articular 
cartilage was scored using a subjective grade (0: normal; 1: minimal 
cartilage fibrillations; 2: moderate cartilage fibrillations; 3: marked 
cartilage fibrillations; 4: cartilage erosion). At the macroscopic 
evaluation, the medial and lateral menisci were removed and placed in 
formalin along with a piece of the synovial membrane from the lateral 
and medial sides. This was done both from the right and left knee. The 
menisci and synovial membrane were sectioned and embedded in 
paraffin for histological evaluation. After macroscopic evaluation, all 
joints were labeled, fixed in 10% neutral formalin for approximately 
one week and then placed in formic acid for decalcification. When the 
decalcification process was complete, all joints were rinsed in buffer, 
sagitally sectioned and embedded in paraffin. Specimens from the 
induced trauma site (the medial meniscus and the articular cartilage 
from the medial tibia and medial femoral condyle), controls from the 
lateral meniscus and the articular cartilage from the lateral tibia and 
the lateral femoral condyle, and the synovial membrane including 
areas containing gel were included in the 5 µm sections of the joints. 
All specimens were stained with Haematoxylin and Eosin (H&E). 
Other stains like Safranin-O, PAS, Masson Tri-chrome, and GFAP 
for nerve fibers were also used. Macro- and micro photographs were 
taken all along, both during the joint dissection procedure and after 
histopathological processing (paraffin embedment, 5 µm sectioning 
and staining).
Nerve endings staining
Three methods were validated in order to identify the presence 
of nerves in the synovial membrane: GFAP (Glial Fibrillary Acidic 
Protein), S100, and anti-neurofilament. A normal looking synovial 
membrane was stained by the three methods. The GFAP stain stained 
nerve endings dark brown whereas the S100 also stained vessels and 
the neurofilament stain did not stain the nerve endings. Three goats 
were used for the nerve staining: 1 goat that was fully sound after 
PAAG treatment, 1 goat that was partly sound after PAAG treatment, 
and 1 control goat.
Joint elasticity investigation
Definitions: Elasticity is defined as maximum strain capacity of the 
tissue, without disruption.
Strain is the ratio of change in a certain length parameter, caused 
by deformation to the original value of the length parameter. It 
is measured in this study as percentage of true max strain (% true 
max strain). It is understood that tissue with higher strain without 
disruption has a higher elasticity; in other words it can be stretched 
more without disruption. For instance, a stiffer joint capsule has 
lower tissue elasticity and a lower % of true max strain.
Stress is the force causing the deformation, divided by the area 
to which the force is applied. In this study the true max stress of the 
tissue was measured, without disruption. It is delivered as true max 
stress in Megapascal (MPa). A tissue with higher true max stress data 
is one having a higher capacity for handling deformation. The elastic 
modulus of a tissue is defined as the slope of its stress-strain curve.
Following euthanasia, a small piece of the lateral and medial sides 
of the right and left knee joint of each of the 6 goats was removed for 
evaluation of joint capsule elasticity. The pieces were approximately 
3x1 cm (length x width) each. The samples were cut out after removal 
of skin using a scalpel, and transported for measurement in a tube 
containing 0.9% saline. The elasticity of the samples was measured 
between 1 and 4 hours post-euthanasia, and the measurements were 
divided over 2 days: 4 goats on Day 1 and 2 goats on Day 2. The 
Instron 5564c was used to measure joint capsule elasticity.
The maximum values of joint capsule elasticity, corresponding to 
the start of rupture, were read off the stress-strain curves presented 
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according to the strain degree. These maximum values were compared 
with the control (i.e. comparison of the value for the treated joint with 
that of the non-treated joint).
This comparison was expressed as a relative deviation and given 
as a percentage. This allowed the effectiveness (positive percentage 
value) or ineffectiveness (negative percentage value) of the treatment 
to be measured.
The values expressed corresponded to the arithmetic average of 
these relative deviations, expressed as a %, and the standard deviation 
from this average for the same data.
Results
Magnetic resonance imaging
MRI showed reduction followed by stabilization of the OA lesions 
(intraarticular bony and cartilaginous lesions) after PAAG treatment 
in 3 goats in the treatment group (Figure 1), while one goat had a mild 
progression of the OA lesions. 
In the control group, all goats had a mild or marked increase of 
the OA lesions (intraarticular bony and cartilaginous lesions) and 
periarticular lesions throughout the study period (Figure 2).
Gross pathology inspection
The left knees (operated knees) showed typical signs of OA. The 
inner synovial lining showed swelling and hyperplasia in all the goats, 
and there was also an uneven cartilage surface due to erosions in 
several foci in all cases (Figure 3). The gel was seen in various amounts 
adhering to the inner side of the joint capsule in all the treated goats 
(Figure 3). Gross inspection of the goats in the treatment group 
showed cartilage lesions and synovial thickening, but this was less 
prominent in this group than in the control group.
Histopathology
The hyperplasia of the inner capsule/synovial membrane that 
was seen at gross inspection was more significant in the treated goats 
than in the control goats. It comprised of angiogenesis, increased 
collagen and perivascular cell density and in the treated goats, also 
the presence of the gel.
Figure 1: Magnetic Resonance image of a goat treated with a 2.5% 
polyacrylamide hydrogel showing osteoarthritic changes at the medial 
femorotibialjoint (Knee). Figure 3: The 2.5% Polyacrylamide hydrogel is present into the joint space, 
adherent to the synovial membrane [Arrow]. Note the osteoarthritic lesion of 
the medial femoral condyle [Arrow head].
Figure 2: Magnetic Resonance image of a control goat showing marked 
periarticular and intraarticularchanges at the medial femorotibialjoint (Knee).
Figure 4: Histopathology of the synovial membrane of a goat’s knee 4 
months after treatment with a 2.5% polyacrylamide hydrogel [HE 10x].
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PAAG injection into the joint cavity added to the thickness of the 
synovial membrane by allowing angiogenesis, collagen and synovial 
cell increase. The gel was seen integrated into the synovial membrane 
(Figures 4 and 5).
In the control goats, there was a minimal synovial membrane 
hyperplasia and an increased amount of collagen (Figures 6 and 7).
In the nerve endings investigation, the nerve endings were 
seen in a similar pattern, whether the goats had had good or minor 
clinical results from the PAAG gel injection or none at all (saline 
only). In all goats used for nerve staining, the nerves were intact with 
normal morphology and in normal numbers (Figure 8). No sign of 
neurotoxicity was observed.
Joint elasticity
Control group:
Lateral side of the joint capsule: Figure 9 depicted the true max 
strain values of the lateral joint capsule from both right (non OA) and 
left (OA) knee joints of one of the control goats.
The lateral side of the joint capsule from the OA left knee showed 
less elasticity (or more stiffness) than the right (non OA) knee with 
-10% on average (+/-5% of SD).
Medial side of the joint capsule: The OA left knee showed less 
elasticity (or more stiffness) than the right (non OA) knee with -20% 
difference. 
In the control group, the lateral and medial sides of the joint 
capsule from the OA control left knee showed less elasticity (or more 
stiffness) than the right (non OA) knee with -10% of elasticity average 
(+/-5% of SD) and -20% on average, respectively.
Treated group:
Lateral side of the joint capsule: Figure 10 showed the true max 
strain values of the lateral joint capsule from the right and left knee 
joint in one on the treated goats. 
The lateral side of the joint capsule from the OA treated left knee 
showed more elasticity (or less stiffness) than the right (non OA) knee 
with +20% on average (+/-23% of SD).
Figure 5: Magnification as in Figure 4. This shows angiogenesis, collagen, 
synovial cell increase and 2.5% polyacrylamide hydrogel [blue vacuoles] 
integrating the synovial membrane [HE 40x].
Figure 7: Magnification as in Figure 6. This shows a minimal synovial 
membrane hyperplasia and an increased amount of collagen [HE 40x].
Figure 6: Histopathology of the synovial membrane of a control goat’s knee 
4 months after intraarticular injection with saline [HE 10x].
Figure 8: Nerve staining of the synovial membrane of the left femorotibial 
joint [Arrows] in a goat treated with 2.5% polyacrylamide hydrogel for 
osteoarthritis [GFAP 4x].
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[17]. No adverse effects were observed in the treated joints of goats 
4 months after the injection of the PAAG [17], which is consistent 
with the safety of PAAG that has been described in horses in the 24 
months follow-up clinical study of OA joints treated with PAAG [15]. 
In addition, intraarticular treatment with PAAG did not have any 
influence on haematology, biochemistry, or acute phase proteins [17].
PAAG (Arthramid Vet) is different from other described 
hydrogels which have different concentration of polyacrylamide, and 
may contain other components as well.
Precise characterization of the mechanism-of-action of PAAG 
on OA joints has not yet been yet established, but histopathological 
observations on joint tissue from the experimental study in goats 
[17], and from horses and rabbits [19], have demonstrated that 
a part of the PAAG, like in other soft tissues, becomes integrated 
within the synovial membrane. PAAG injected 4 months earlier into 
an experimentally induced OA joint induced a moderate synovial 
hyperplasia of the inner side of the joint capsule with integrated gel, 
angiogenesis and collagen production [17]. A similar tissue reaction 
was seen in horses with osteoarthritic joints that were injected with 
PAAG, including cases treated 2 years earlier with PAAG [19].
PAAG has been found to be present in the joint cavity in all 
the goats [17], as well as in horses treated with PAAG [19]. PAAG 
is a non-degradable and highly viscous product [8] and thus might 
contribute to protecting the articular surface of an osteoarthritic joint, 
and hence it could reduce and stabilize the OA lesions. Lack of joint 
lubrication is postulated to play a significant role in the pathogenesis 
of OA [20]. This emphasizes the role of viscosupplementation, and 
hence the improvement of lubrication within the joint, in protecting 
a joint suffering from OA, and reducing the resulting pain. Recently, 
a study supported the use of intra-articular lubricin as an adjunct 
to viscosupplementation for retarding cartilage degeneration and 
possibly the development of post-traumatic OA [21,22].
MRI follow-up showed reduction followed by stabilization of the 
OA lesions after PAAG treatment in goats
The joint capsule elasticity investigation has shown that the 
capsule of the joints injected with PAAG had a better elasticity when 
compared to the joint capsule of the control joints. OA joints typically 
show joint stiffness which is a major source of pain in OA. This is 
supported by a recent study on knee joint stiffness in humans, which 
has shown that stiffness co-efficient, was higher in individuals with 
painful OA [23]. 
By integrating the synovial membrane, which may probably 
decrease the joint capsule and the joint stiffness, PAAG might relieve 
pain of the OA joint. This theory is supported by clinical observations 
in the clinical trials in horses [14,15], where OA joint that responded 
well to PAAG are no more painful to joint flexion after having been 
painful to joint flexion before treatment.
Although conventional concepts of OA emphasize the direct and 
predominant involvement of cartilage and bone in OA development, 
it is increasingly recognized that the synovium also contributes to the 
central pathophysiological event of cartilage matrix depletion.
This study presents some preliminary observations of the 
mechanisms of action of PAAG on OA joints. Preliminary pathology 
Figure 9: Comparison of joint capsule elasticity of an osteoarthritic knee 
(lateral) vs. non osteoarthritic knee (lateral) in one of the control goats.
Figure 10: Comparison of joint capsule elasticity of an osteoarthritic knee 
(lateral) vs. non osteoarthritic knee (lateral) in one of the treated goats.
Figure 11: Comparison of joint capsule elasticity of an osteoarthritic knee 
(medial) vs. non osteoarthritic knee (medial) in one of the treated goats.
Medial side of the joint capsule: Figure 11 showed the true max 
strain values of the medial joint capsule from the right and left knee 
joint from one of the treated goats. 
The medial side of the joint capsule from the OA treated left knee 
showed more elasticity (or less stiffness) than the right (non OA) knee 
with +40% on average (+/-18% of SD).
In the treated goats, the lateral and medial side of the joint capsule 
from the OA treated left knee showed more elasticity (or less stiffness) 
than the right (non OA) knee with +20% of true max stress average 
(+/-23% of SD) and +40% on average (+/-18% SD), respectively.
No adverse effects associated with the treated joints were detected 
during the study period.
Discussion
The 2.5% PAAG is a novel and promising treatment for OA and 
its clinical efficacy was reported in horses [14-16] and in a goat model 
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and joint capsule elasticity data suggest that PAAG by acting mainly 
on the soft tissue of the joint, in particular the synovial membrane 
may reduce the overall joint capsule stiffness, a major source of pain 
in the OA joint. On the other hand, MRI and pathology investigations 
have further revealed stabilization of the OA lesions in the PAAG 
treated goats, possibly caused by the high viscosupplementation, and 
thus protective effect of PAAG.
In addition, PAAG significantly alleviated lameness in OA joints, 
as assessed by clinical lameness evaluation (ground and treadmill 
evaluations) [17]. In the 24 months follow-up in horses, the largest 
reduction in lameness score appeared from baseline to month 1. Thus, 
the clinical improvement in lameness score was already present one 
month after PAAG treatment. This suggests that the effect of PAAG 
on OA might occur mainly during the first month after treatment and 
lasts and increases progressively until 6 months, with a stabilization 
between 6 and 24 months [15]. This 24 months follow up trial has also 
demonstrated that joint effusion score decreases significantly over 
time (p<0.0001). Although joint effusion was subjectively assessed in 
the horse study, PAAG induced a significant decrease in joint effusion 
in the OA joints. However, the mechanism-of-action of PAAG in 
reducing joint effusion in OA joints needs to be investigated. In the 
experimental OA model in goats [17], joint effusion was not observed, 
and thus not evaluated.
These preliminary observations of the mechanisms of action 
of PAAG emphasize the role of synovial membrane and joint 
capsule, as well as the role of the long acting viscosupplementation, 
in the treatment of OA. This certainly opens new horizons in the 
understanding of OA and its treatment.
Further studies are needed to understand more the mechanisms 
of action of PAAG in improving clinical signs of OA and in stabilizing 
its progression. 
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